Clinical Guideline Alerts February 2024 Banner
  • Corneal Ectasia
    • Published by American Academy of Ophthalmology (AAO) on February 12, 2024
  • Conjunctivitis
    • Published by American Academy of Ophthalmology (AAO) on February 12, 2024
  • Adult Strabismus
    • Published by American Academy of Ophthalmology (AAO) on February 12, 2024
  • Blepharitis
    • Published by American Academy of Ophthalmology (AAO) on February 11, 2024
  • Dry Eye Syndrome
    • Published by American Academy of Ophthalmology (AAO) on February 11, 2024
  • Bacterial Keratitis
    • Published by American Academy of Ophthalmology (AAO) on February 11, 2024
FDA Approvals Banner
  • Imbruvica (Janssen)New Formulation 
    • Oral suspension formulation for adult patients in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • Exblifep (Allecra Therapeutics) 
    • Treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
  • Biktarvy (Gilead)Expanded Indication 
    • To treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance.
  • Simlandi (Teva / Alvotech)Biosimilar to Humira
    • Interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
  • Tagrisso (AstraZeneca)New Indication
    • Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
  • Xolair (Novartis / Genentech) New Indication
    • For reducing allergic reactions to foods in adults and most children. The drug is meant to be taken regularly by patients with food allergies to reduce the risk for reactions, including anaphylaxis, in case of accidental exposure to one or more allergens.
  • Amtagvi (Iovance Biotherapeutics)
    • Treatment of certain adults with unresectable or metastatic melanoma.
  • Aurlumyn (Actelion Pharmaceuticals) 
    • To treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Onivyde (Ipsen)New Indication
    • First-line treatment in adults living with metastatic pancreatic adenocarcinoma (mPDAC).
  • Eohilia (Takeda) 
    • For people 11 years and older with eosinophilic esophagitis (EoE).

Copyright © 2024 Guideline Central, All rights reserved.